215. Tetralogy of Fallot Clinical trials / Disease details
Clinical trials : 22 / Drugs : 48 - (DrugBank : 19) / Drug target genes : 18 - Drug target pathways : 49
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01971593 (ClinicalTrials.gov) | August 2013 | 23/10/2013 | The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease | Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease | Tetralogy of Fallot;Transposition of the Great Vessels With an Arterial Switch;Single Ventricle With a Fontan Palliation | Drug: Eplerenone | Washington University School of Medicine | Pfizer | Terminated | 18 Years | 80 Years | All | 26 | Phase 4 | United States |